| Lymphoma, Follicular
Breyanzi vs Gazyva
Side-by-side clinical, coverage, and cost comparison for lymphoma, follicular.Deep comparison between: Breyanzi vs Gazyva with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsGazyva has a higher rate of injection site reactions vs Breyanzi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Gazyva but not Breyanzi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Breyanzi
Gazyva
At A Glance
IV infusion
Single infusion
CD19-directed CAR T cell therapy
IV infusion
Anti-CD20 monoclonal antibody
Indications
- Diffuse Large B-Cell Lymphoma
- High grade B-cell lymphoma
- Mediastinal (Thymic) Large B-Cell Lymphoma
- Lymphoma, Follicular
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Mantle cell lymphoma
- Marginal Zone B-Cell Lymphoma
- Chronic Lymphocytic Leukemia
- Lymphoma, Follicular
- Lupus Nephritis
Dosing
Diffuse Large B-Cell Lymphoma, High grade B-cell lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma (after one line of therapy) 90 to 110 x 10^6 CAR-positive viable T cells as a single IV infusion, administered 2 to 7 days after lymphodepleting chemotherapy (fludarabine 30 mg/m2/day IV and cyclophosphamide 300 mg/m2/day IV for 3 days).
Diffuse Large B-Cell Lymphoma, High grade B-cell lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma (after two or more lines of therapy) 50 to 110 x 10^6 CAR-positive viable T cells as a single IV infusion, administered 2 to 7 days after lymphodepleting chemotherapy (fludarabine 30 mg/m2/day IV and cyclophosphamide 300 mg/m2/day IV for 3 days).
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoma, Follicular, Mantle cell lymphoma, Marginal Zone B-Cell Lymphoma 90 to 110 x 10^6 CAR-positive viable T cells as a single IV infusion, administered 2 to 7 days after lymphodepleting chemotherapy (fludarabine 30 mg/m2/day IV and cyclophosphamide 300 mg/m2/day IV for 3 days).
Chronic Lymphocytic Leukemia 100 mg IV on day 1 and 900 mg on day 2 of Cycle 1, then 1,000 mg on days 8 and 15 of Cycle 1, and 1,000 mg on day 1 of Cycles 2-6 (28-day cycles) in combination with chlorambucil.
Lymphoma, Follicular 1,000 mg IV on days 1, 8, and 15 of Cycle 1, then 1,000 mg on day 1 of Cycles 2-6 or 2-8 in combination with chemotherapy; responding patients continue on 1,000 mg monotherapy every 2 months for up to 2 years.
Lupus Nephritis 1,000 mg IV at initial infusion (Dose 1), at Week 2 (Dose 2), at Week 24 (Dose 3), at Week 26 (Dose 4), then 1,000 mg every 6 months thereafter, in combination with standard therapy.
Contraindications
—
- Known hypersensitivity reaction (e.g., anaphylaxis) to obinutuzumab or any excipient
- Serum sickness with prior obinutuzumab use
Adverse Reactions
Most common (>=30%) fever, CRS, fatigue, musculoskeletal pain, nausea
Serious CRS, encephalopathy, febrile neutropenia, sepsis, pneumonia, fever, hemorrhage, renal failure, aphasia, delirium, hemophagocytic lymphohistiocytosis
Postmarketing immune effector cell-associated neurotoxicity syndrome (ICANS), T cell malignancies, blindness
Most common (>=10%) Infusion-related reactions, neutropenia, thrombocytopenia, diarrhea, fatigue, upper respiratory tract infection, musculoskeletal pain
Serious Hepatitis B virus reactivation, progressive multifocal leukoencephalopathy, infusion-related reactions, hypersensitivity reactions including serum sickness, tumor lysis syndrome, infections, neutropenia, thrombocytopenia, disseminated intravascular coagulation
Postmarketing Serum sickness
Pharmacology
BREYANZI is a CD19-directed genetically modified autologous T cell immunotherapy; CAR binding to CD19 on tumor and normal B cells triggers CD3 zeta-mediated activation and cytotoxic killing of target cells, while 4-1BB (CD137) costimulatory signaling enhances CAR T cell expansion and persistence.
Obinutuzumab is a humanized anti-CD20 IgG1 monoclonal antibody with reduced fucose content that mediates B-cell lysis via immune effector cell engagement (ADCC and ADCP), direct intracellular death signaling, and complement activation; its reduced fucose content confers greater ADCC activity than rituximab.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Breyanzi
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
Gazyva
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Breyanzi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Gazyva
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Breyanzi
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Gazyva
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Chronic Lymphocytic Leukemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Chronic Lymphocytic Leukemia (CLL)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BreyanziView full Breyanzi profile
GazyvaView full Gazyva profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.